Depression is one of the most common mental health conditions in the world. Millions of people struggle with sadness, loss of interest, low energy, anxiety, and feelings of hopelessness every day.
For some people, depression lasts for months or even years and can greatly affect work, relationships, sleep, and overall quality of life.
Doctors often treat depression with antidepressant medications called SSRIs. These medicines can help many people, but they do not work for everyone. Some patients wait several weeks before feeling any improvement, while others experience side effects such as nausea, weight changes, tiredness, or emotional numbness.
Because of these challenges, scientists have been searching for faster and more effective treatments for depression.
A new study from researchers at Karolinska Institutet in Sweden now suggests that psilocybin, the psychedelic compound found in so-called “magic mushrooms,” may offer rapid relief for depressive symptoms.
The study was published in JAMA Network Open and is the first randomized, double-blind study in Sweden to test psilocybin for depression.
Researchers found that a single dose of psilocybin produced noticeable improvement in depressive symptoms within only a few days. Some benefits lasted for more than three months.
The study included 35 adults aged between 20 and 65 who had moderate to severe recurrent depression.
Participants were randomly divided into two groups. One group received a single 25-milligram dose of psilocybin, while the other group received an active placebo made from niacin, a vitamin that can produce mild physical sensations such as warmth or flushing.
Both groups also received psychotherapeutic support before, during, and after treatment. Researchers wanted to make sure participants were emotionally supported throughout the experience.
On the treatment day, participants wore eye masks, listened to music through headphones, and were encouraged to focus inwardly during the session.
Researchers measured depression symptoms using a standard medical tool called the Montgomery–Åsberg Depression Rating Scale, also known as MADRS.
Eight days after treatment, people who received psilocybin showed a much larger reduction in depression scores compared to those who received the placebo.
The psilocybin group improved by an average of 9.7 points, while the placebo group improved by only 2.4 points.
Researchers considered this difference both statistically significant and clinically meaningful.
Participants also filled out their own self-assessments. These reports suggested that some people experienced improvements as early as two days after treatment.
The antidepressant effects continued after 15 days and 42 days.
After six weeks, 53% of participants who received psilocybin were considered to be in remission from depression. In the placebo group, only 6% reached remission.
One year later, many participants in the psilocybin group were still in remission. However, researchers noted that by that point many participants from the placebo group had also recovered, making differences between groups less clear.
The researchers believe the findings are promising because rapid relief is especially important for people experiencing severe depression.
Lead author Hampus Yngwe explained that psilocybin may someday become an alternative option when faster symptom reduction is needed.
However, researchers also emphasized that the treatment is not without risks.
Most side effects during the study were mild or moderate and temporary. However, two participants experienced severe and long-lasting anxiety that required medical care.
The researchers stressed that psychedelic treatments should only be carried out in carefully controlled medical settings with professional supervision.
Another important issue involves the study design itself.
Because psilocybin creates very noticeable psychological effects, many participants could guess whether they had received the active treatment or placebo.
Researchers say this may influence results because expectations alone can sometimes affect how people feel.
Scientists therefore want future studies to better understand how much of the antidepressant effect comes from the drug itself and how much may be linked to expectations and psychological support.
Researchers are also continuing to investigate how psilocybin affects the brain biologically.
Some studies suggest depression may involve reduced communication between brain regions and changes in connections between nerve cells.
Animal studies have shown that psychedelic substances may stimulate the growth of synapses, which are the connections that allow brain cells to communicate.
The research team plans to study brain scans, blood tests, and spinal fluid samples collected during the trial to better understand these effects.
Although larger studies are still needed, the findings add to growing scientific interest in psychedelic-assisted therapy for mental health conditions.
Experts say psilocybin is not yet a routine treatment for depression, but the study suggests it may become an important area of future psychiatric research.
If you care about mental health, please read studies about 6 foods you can eat to improve mental health, and B vitamins could help prevent depression and anxiety.
For more health information, please see recent studies about how dairy foods may influence depression risk, and results showing Omega-3 fats may help reduce depression.
The study was published in JAMA Network Open.
Source: Karolinska Institutet.
